Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 209
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Science ; 225(4661): 514-6, 1984 Aug 03.
Article in English | MEDLINE | ID: mdl-6429856

ABSTRACT

Apolipoproteins A-1 and A-2 were purified from human plasma. At concentrations present in human bile these proteins prolonged the nucleation time of cholesterol monohydrate crystals when added to model systems of supersaturated bile. In contrast, apolipoprotein C-3 and other serum proteins did not have this effect. Also, when human gallbladder bile was fractionated by gel filtration chromatography, apolipoproteins A-1 and A-2 were among the proteins present in a fraction of bile enriched in potent inhibitors of cholesterol crystal nucleation. These findings suggest that apolipoproteins A-1 and A-2 in supersaturated human gallbladder bile could inhibit the rate of formation of solid cholesterol crystals and thus help to prevent spontaneous cholesterol gallstone formation in humans.


Subject(s)
Apolipoproteins/blood , Bile/physiology , Cholesterol/metabolism , Lipoproteins, HDL/blood , Apolipoprotein A-I , Apolipoprotein A-II , Crystallization , Gallbladder/physiology , Humans , Kinetics , Models, Biological
2.
J Clin Invest ; 64(4): 948-54, 1979 Oct.
Article in English | MEDLINE | ID: mdl-113427

ABSTRACT

Three lysosomal glycosidases, beta-glucuronidase (EC 3.2.1.31), beta-galactosidase (EC 3.2.1.23), and N-acetyl-beta-glucosaminidase (EC 3.2.1.30) have been investigated in bile that was freshly collected from rats through a complete bile fistula. Assay conditions have been established on the basis of appropriate kinetic studies. The biliary excretion patterns for these enzymes were found to vary considerably from rat to rat during the 24-h collection period. In a given animal, however, the three hydrolases were excreted in parallel and showed a gradual increase in activity with time, most marked after 10- 12 h of collection. 24-h biliary outputs of the three hydrolases averaged congruent with3% of their respective contents in total liver, and bile diversion had no effect on hepatic glycosidase activity or total protein content. Other enzymes known to be associated primarily with mitochondria, endoplasmic reticulum, and cell sap were also detected in bile, generally in smaller amounts. The biliary excretion of the plasma membrane markers, alkaline phosphodiesterase I and 5'-nucleotidase, however, was comparable to that of the lysosomal hydrolases. Biliary excretion of total protein was relatively constant and corresponded to 3.0% of the total hepatic protein content per day, whereas biliary bile acid secretion decreased during the first 12 h and then remained constant. Exocytic bulk discharge of hepatocyte lysosomes is proposed as the most likely mechanism for the biliary excretion of lysosomal enzymes. These results call attention to the possible pathophysiologic significance of biliary excretion of hepatic lysosomal contents as a means of residue disposal.


Subject(s)
Bile/enzymology , Galactosidases/metabolism , Glucuronidase/metabolism , Glycoside Hydrolases/metabolism , beta-Galactosidase/metabolism , Animals , Exocytosis , Glucose , Lactose , Liver/metabolism , Lysosomes/metabolism , Male , Rats , Time Factors
3.
J Clin Invest ; 77(1): 90-7, 1986 Jan.
Article in English | MEDLINE | ID: mdl-3944262

ABSTRACT

In these experiments, we assessed the role of hepatocyte lysosomes in biliary excretion of iron. We loaded rats with iron by feeding 2% carbonyl iron and collected bile for 24 h via bile fistulae from iron-loaded and control rats. In additional rats, bile was collected before and after the administration of colchicine. Rats were then killed and their livers were homogenized and fractionated for biochemical analyses or processed for electron microscopy and x-ray microanalysis. Inclusion of 2% carbonyl iron in the diet caused a 45-fold increase (P less than 0.001) in hepatic iron concentration compared with controls (1,826 +/- 159 vs. 38 +/- 6.7 micrograms/g liver, mean +/- SE). Electron microscopy with quantitative morphometry and x-ray microanalysis showed that the excess iron was sequestered in an increased number of lysosomes concentrated in the pericanalicular region of the hepatocyte. Iron loading was also associated with a twofold increase in biliary iron excretion (4.06 +/- 0.3 vs. 1.75 +/- 0.1 micrograms/g liver/24 h; P less than 0.001). In contrast, the biliary outputs of three lysosomal enzymes were significantly lower (P less than 0.0005) in iron-loaded rats compared with controls (mean +/- SE) expressed as mU/24 h/g liver: N-acetyl-beta-glucosaminidase, 26.7 +/- 4.6 vs. 66.2 +/- 13.4; beta-glucuronidase, 10.1 +/- 1.3 vs. 53.2 +/- 17.9; beta-galactosidase, 8.9 +/- 1.0 vs. 15.4 +/- 2.3. In iron-loaded rats but not in controls, biliary iron excretion was coupled to the release into bile of each of the three lysosomal hydrolases as assessed by linear regression analysis (P less than 0.001). In contrast, no relationships were found between biliary iron excretion and the biliary outputs of a plasma membrane marker enzyme (alkaline phosphodiesterase I) or total protein. After administration of colchicine, there was a parallel increase in biliary excretion of iron and lysosomal enzymes in iron-loaded rats, but not controls. We interpret these data to indicate that, in the rat, biliary iron excretion from hepatocyte lysosomes is an important excretory route for excess hepatic iron.


Subject(s)
Bile/metabolism , Iron/metabolism , Liver/metabolism , Lysosomes/metabolism , Acetylglucosaminidase/metabolism , Animals , Aspartate Aminotransferases/blood , Bile/enzymology , Bilirubin/blood , Body Weight , Colchicine/pharmacology , Electron Probe Microanalysis , Liver/enzymology , Liver/ultrastructure , Lysosomes/enzymology , Lysosomes/ultrastructure , Male , Organ Size , Rats , Rats, Inbred Strains , Subcellular Fractions/metabolism , Time Factors , Ultracentrifugation
4.
J Clin Invest ; 88(4): 1207-15, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1918375

ABSTRACT

While hemochromatosis is characterized by sequestration of iron-protein complexes in hepatocyte lysosomes, little is known about the effects of excess iron on these organelles. Therefore, we studied the effects of experimental iron overload on hepatocyte lysosomal structure, physicochemical properties, and function in rats fed carbonyl iron. A sixfold increase (P less than 0.0001) in hepatic iron and a fivefold increase in lysosomal iron (P less than 0.01) was observed after iron loading; as a result, hepatocyte lysosomes became enlarged and misshapen. These lysosomes displayed increased (P less than 0.0001) fragility; moreover, the fluidity of lysosomal membranes isolated from livers of iron-loaded rats was decreased (P less than 0.0003) as measured by fluorescence polarization. Malondialdehyde, an end product of lipid peroxidation, was increased by 73% (P less than 0.008) in lysosomal membranes isolated from livers of iron-overloaded rats. While amounts of several individual fatty acids in isolated lysosomal membranes were altered after iron overload, cholesterol/phospholipid ratios, lipid/protein ratios, double-bond index, and total saturated and unsaturated fatty acids remained unchanged. The pH of lysosomes in hepatocytes isolated from livers of iron-loaded rats and measured by digitized video microscopy was increased (control, 4.70 +/- 0.05; iron overload, 5.21 +/- 0.10; P less than 0.01). Our results demonstrate that experimental iron overload causes marked alterations in hepatocyte lysosomal morphology, an increase in lysosomal membrane fragility, a decrease in lysosomal membrane fluidity, and an increase in intralysosomal pH. Iron-catalyzed lipid peroxidation is likely the mechanism of these structural, physicochemical, and functional disturbances.


Subject(s)
Iron/toxicity , Liver/drug effects , Lysosomes/drug effects , Animals , Hydrogen-Ion Concentration , Iron/analysis , Lipid Peroxidation/drug effects , Liver/metabolism , Liver/pathology , Lysosomes/metabolism , Lysosomes/pathology , Male , Membrane Fluidity/drug effects , Membrane Lipids/analysis , Organ Size/drug effects , Rats , Rats, Inbred Strains
5.
J Clin Invest ; 108(2): 223-32, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11457875

ABSTRACT

The close association between autoantibodies against pyruvate dehydrogenase-E2 (PDC-E2), a ubiquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained. Many autoantigens are selectively modified during apoptosis, which has focused attention on apoptotic cells as a potential source of "neo-antigens" responsible for activating autoreactive lymphocytes. Since increased apoptosis of bile duct epithelial cells (cholangiocytes) is evident in patients with PBC, we evaluated the effect of apoptosis on PDC-E2. Autoantibody recognition of PDC-E2 by immunofluorescence persisted in apoptotic cholangiocytes and appeared unchanged by immunoblot analysis. PDC-E2 was neither cleaved by caspases nor concentrated into surface blebs in apoptotic cells. In other cell types, autoantibody recognition of PDC-E2, as assessed by immunofluorescence, was abrogated after apoptosis, although expression levels of PDC-E2 appeared unchanged when examined by immunoblot analysis. Both overexpression of Bcl-2 and depletion of glutathione before inducing apoptosis prevented this loss of autoantibody recognition, suggesting that glutathiolation, rather than degradation or loss, of PDC-E2 was responsible for the loss of immunofluorescence signal. We postulate that apoptotic cholangiocytes, unlike other apoptotic cell types, are a potential source of immunogenic PDC-E2 in patients with PBC.


Subject(s)
Apoptosis , Autoantigens/metabolism , Bile Ducts/metabolism , Liver Cirrhosis, Biliary/metabolism , Pyruvate Dehydrogenase Complex/metabolism , Apoptosis/immunology , Autoantibodies/immunology , Autoantigens/analysis , Autoantigens/immunology , Bile Ducts/pathology , Cell Line/radiation effects , Dihydrolipoyllysine-Residue Acetyltransferase , Dithiothreitol/pharmacology , Epithelial Cells/metabolism , Epithelial Cells/pathology , Fluorescent Antibody Technique , Gene Expression Regulation, Enzymologic , Genes, bcl-2 , Glutathione/metabolism , Glutathione/pharmacology , Humans , Immune Sera , Immunoblotting , Liver Cirrhosis, Biliary/immunology , Liver Cirrhosis, Biliary/pathology , Lymphocyte Activation/immunology , Mitochondria/metabolism , Pyruvate Dehydrogenase Complex/analysis , Pyruvate Dehydrogenase Complex/immunology , Transfection
6.
J Clin Invest ; 80(3): 750-7, 1987 Sep.
Article in English | MEDLINE | ID: mdl-3476497

ABSTRACT

Transforming growth factor beta (TGF beta), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGF beta, we performed studies to examine the hepatic processing of biologically active 125I-TGF beta in the rat. After intravenous injection, 125I-TGF beta disappeared from the plasma with an initial t1/2 of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGF beta by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGF beta on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGF beta (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGF beta (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGF beta by the liver. After extraction, TGF beta undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGF beta.


Subject(s)
Bile/metabolism , Liver/metabolism , Peptides/metabolism , Animals , Chloroquine/pharmacology , Leupeptins/pharmacology , Liver/ultrastructure , Male , Organoids/metabolism , Rats , Transforming Growth Factors
7.
J Clin Invest ; 83(1): 30-9, 1989 Jan.
Article in English | MEDLINE | ID: mdl-2910913

ABSTRACT

We investigated the hypothesis that lysosomes are the main source of biliary copper in conditions of hepatic copper overload. We used a rat model of oral copper loading and studied the relationship between the biliary output of copper and lysosomal hydrolases. Male Sprague-Dawley rats were given tap water with or without 0.125% copper acetate for up to 36 wk. Copper loading produced a 23-fold increase in the hepatic copper concentration and a 30-65% increase in hepatic lysosomal enzyme activity. Acid phosphatase histochemistry showed that copper-loaded livers contained an increased number of hepatocyte lysosomes; increased copper concentration of these organelles was confirmed directly by both x ray microanalysis and tissue fractionation. The copper-loaded rats showed a 16-fold increase in biliary copper output and a 50-300% increase in biliary lysosomal enzyme output. In the basal state, excretory profiles over time were similar for biliary outputs of lysosomal enzymes and copper in the copper-loaded animals but not in controls. After pharmacologic stimulation of lysosomal exocytosis, biliary outputs of copper and lysosomal hydrolases in the copper-loaded animals remained coupled: injection of colchicine or vinblastine produced an acute rise in the biliary output of both lysosomal enzymes and copper to 150-250% of baseline rates. After these same drugs, control animals showed only the expected increase in lysosomal enzyme output without a corresponding increase in copper output. We conclude that the hepatocyte responds to an increased copper load by sequestering excess copper in an increased number of lysosomes that then empty their contents directly into bile. The results provide direct evidence that exocytosis of lysosomal contents into biliary canaliculi is the major mechanism for biliary copper excretion in hepatic copper overload.


Subject(s)
Bile/metabolism , Copper/metabolism , Liver/cytology , Lysosomes/metabolism , Acid Phosphatase/analysis , Animals , Electron Probe Microanalysis , Glucuronidase/metabolism , Liver/metabolism , Lysosomes/enzymology , Male , Microscopy, Electron , Rats , Rats, Inbred Strains
8.
J Clin Invest ; 80(4): 1200-4, 1987 Oct.
Article in English | MEDLINE | ID: mdl-3654978

ABSTRACT

Deficiency of serum ceruloplasmin is a characteristic biochemical abnormality of Wilson's disease, although the mechanism of this finding is unknown. Ceruloplasmin messenger RNA (mRNA) levels were therefore examined in five patients with Wilson's disease and five controls with other types of hepatic disease. Northern and dot blot hybridizations showed that detectable ceruloplasmin mRNA was present in all of the patients with Wilson's disease, including one patient with no detectable serum ceruloplasmin. However, the ceruloplasmin mRNA levels in the Wilson's disease patients were only 33% that of controls (P less than 0.001). In contrast, albumin mRNA levels in the Wilson's disease patients averaged 161% that of controls. In an attempt to better delineate the level of gene expression responsible for this decrease in ceruloplasmin mRNA, the nuclear run-on assay was used to analyze transcriptional rates. The amount of ceruloplasmin gene transcription in four Wilson's patients was decreased to 44% that of three controls. These results indicate that the diminished serum ceruloplasmin levels in patients with Wilson's disease are due at least in part to a decrease in ceruloplasmin gene transcription.


Subject(s)
Ceruloplasmin/deficiency , Hepatolenticular Degeneration/genetics , Ceruloplasmin/genetics , Hepatolenticular Degeneration/blood , Humans , Nucleic Acid Hybridization , RNA, Messenger/analysis , Serum Albumin/genetics , Transcription, Genetic
9.
J Clin Invest ; 100(11): 2714-21, 1997 Dec 01.
Article in English | MEDLINE | ID: mdl-9389734

ABSTRACT

Although bile acid transport by bile duct epithelial cells, or cholangiocytes, has been postulated, the details of this process remain unclear. Thus, we performed transport studies with [3H]taurocholate in confluent polarized monolayers of normal rat cholangiocytes (NRC). We observed unidirectional (i.e., apical to basolateral) Na+-dependent transcellular transport of [3H]taurocholate. Kinetic studies in purified vesicles derived from the apical domain of NRC disclosed saturable Na+-dependent uptake of [3H]taurocholate, with apparent Km and Vmax values of 209+/-45 microM and 1.23+/-0.14 nmol/mg/10 s, respectively. Reverse transcriptase PCR (RT-PCR) using degenerate primers for both the rat liver Na+-dependent taurocholate-cotransporting polypeptide and rat ileal apical Na+-dependent bile acid transporter, designated Ntcp and ASBT, respectively, revealed a 206-bp product in NRC whose sequence was identical to the ASBT. Northern blot analysis demonstrated that the size of the ASBT transcript was identical in NRC, freshly isolated cholangiocytes, and terminal ileum. In situ RT-PCR on normal rat liver showed that the message for ASBT was present only in cholangiocytes. Immunoblots using a well-characterized antibody for the ASBT demonstrated a 48-kD protein present only in apical membranes. Indirect immunohistochemistry revealed apical localization of ASBT in cholangiocytes in normal rat liver. The data provide direct evidence that conjugated bile acids are taken up at the apical domain of cholangiocytes via the ASBT, and are consistent with the notion that cholangiocyte physiology may be directly influenced by bile acids.


Subject(s)
Bile Acids and Salts/metabolism , Bile Ducts/metabolism , Carrier Proteins/metabolism , Organic Anion Transporters, Sodium-Dependent , Symporters , Animals , Bile Ducts/cytology , Biological Transport , Carrier Proteins/genetics , Cells, Cultured , Male , RNA , Rats , Rats, Inbred F344 , Taurocholic Acid/metabolism
10.
Cancer Res ; 61(17): 6388-93, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11522631

ABSTRACT

NO-mediated inhibition of base excision DNA repair may potentiate oxidativeDNA damage in cells and could be relevant to carcinogenesis associated with chronic inflammation. Because 8-oxoguanine, a ubiquitous oxidative DNA lesion, is repaired predominantly by human 8-oxoguanine glycosylase (hOgg1), our aim was to determine whether NO directly inhibits its repair activity. Neither induction of NO-generating enzyme inducible NO synthase nor treatment with S-nitroso-N-acetyl-D-L-pencillamine altered expression of hOgg1 in a human cholangiocarcinoma cell line (KMBC). In contrast, both treatments completely inhibited activity of hOgg1 immunoprecipitated from KMBC cells overexpressing hOgg1 and in a cell-free system. Both NO and peroxynitrite were capable of inhibiting hOgg1 activity. Inhibition of hOgg1 protein was characterized by formation of S-nitrosothiol adducts and loss/ejection of zinc ions. Our data indicate that NO, an inflammatory mediator, directly inhibits a key base excision repair enzyme (hOgg1) responsible for base excision repair of 8-oxoguanine. These data support the concept that NO-mediated inhibition of DNA contributes to the mutagenic environment of chronic inflammation.


Subject(s)
DNA Repair/drug effects , Guanine/analogs & derivatives , N-Glycosyl Hydrolases/antagonists & inhibitors , Nitric Oxide/pharmacology , Cholangiocarcinoma/genetics , Cholangiocarcinoma/metabolism , DNA Damage , DNA Repair/physiology , DNA, Complementary/genetics , DNA-Formamidopyrimidine Glycosylase , Gene Expression , Guanine/metabolism , Humans , N-Glycosyl Hydrolases/genetics , N-Glycosyl Hydrolases/metabolism , Nitrates/metabolism , Nitrates/pharmacology , Nitrosation/drug effects , Oxidants/pharmacology , Oxidation-Reduction , Precipitin Tests , Transfection , Tumor Cells, Cultured , Zinc/metabolism
11.
Cancer Res ; 60(1): 184-90, 2000 Jan 01.
Article in English | MEDLINE | ID: mdl-10646872

ABSTRACT

Chronic infection and inflammation are risk factors for the development of cholangiocarcinoma, a highly malignant, generally fatal adenocarcinoma originating from biliary epithelia. However, the link between inflammation and carcinogenesis in these disorders is obscure. Because nitric oxide (NO) is generated in inflamed tissues by inducible nitric oxide synthase (iNOS) and because DNA repair proteins are potentially susceptible to NO-mediated nitrosylation, we formulated the hypothesis that inflammatory cytokines induce iNOS and sufficient NO to inhibit DNA repair enzymes leading to the development and progression of cholangiocarcinoma. iNOS and nitrotyrosine were demonstrated in 18/18 cholangiocarcinoma specimens. Furthermore, iNOS and NO generation could be induced in vitro by inflammatory cytokines (mixture of interleukin-1beta, IFN-gamma, and tumor necrosis factor alpha) in three human cholangiocarcinoma cell lines. NO-dependent DNA damage as assessed by the comet assay was demonstrated during exposure of the three cholangiocarcinoma cell lines to cytokines. Moreover, global DNA repair activity was inhibited by 70% by a NO-dependent process after exposure of cells to cytokines. Our data indicate that activation of iNOS and excess production of NO in response to inflammatory cytokines cause DNA damage and inhibit DNA repair proteins. NO inactivation of DNA repair enzymes may provide a link between inflammation and the initiation, promotion, and/or progression of cholangiocarcinoma.


Subject(s)
Bile Duct Neoplasms/metabolism , Bile Ducts, Intrahepatic , Cholangiocarcinoma/metabolism , DNA Damage , DNA Repair , Neoplasm Proteins/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Animals , Cholangiocarcinoma/genetics , Cholangitis/metabolism , Enzyme Induction , Humans , Interferon-gamma/pharmacology , Interleukin-1/pharmacology , Nitric Oxide Synthase Type II , Rats , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology
12.
Arch Intern Med ; 149(6): 1279-84, 1989 Jun.
Article in English | MEDLINE | ID: mdl-2658897

ABSTRACT

Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium--gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83%) of 24 patients were cured following mezlocillin therapy compared with 9 (41%) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.


Subject(s)
Ampicillin/therapeutic use , Cholangitis/drug therapy , Gentamicins/therapeutic use , Mezlocillin/therapeutic use , Adult , Aged , Aged, 80 and over , Ampicillin/adverse effects , Ampicillin/metabolism , Cholangitis/microbiology , Creatinine/blood , Drug Resistance, Microbial , Drug Therapy, Combination/therapeutic use , Enterobacter/drug effects , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Female , Gentamicins/adverse effects , Gentamicins/metabolism , Humans , Klebsiella/drug effects , Klebsiella/isolation & purification , Male , Mezlocillin/adverse effects , Mezlocillin/metabolism , Middle Aged , Prospective Studies , Random Allocation
13.
Am J Med ; 89(1): 73-80, 1990 Jul.
Article in English | MEDLINE | ID: mdl-2195892

ABSTRACT

Primary sclerosing cholangitis is an increasingly recognized chronic cholestatic liver disease. It frequently occurs in association with chronic ulcerative colitis and is characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The cause is unknown, although many mechanisms have been considered, including infectious, toxic, and immunologic. The prognosis varies. No adequate treatment exists, although a number of potential treatments have been evaluated in uncontrolled trials, and the results of controlled trials have only recently been reported. Liver transplantation has recently been shown to be an effective treatment for end-stage disease. These various advances in our understanding of primary sclerosing cholangitis are reviewed.


Subject(s)
Cholangitis, Sclerosing , Cholangitis, Sclerosing/diagnosis , Cholangitis, Sclerosing/etiology , Cholangitis, Sclerosing/therapy , Humans
14.
Am J Med ; 80(6): 1237-41, 1986 Jun.
Article in English | MEDLINE | ID: mdl-3524213

ABSTRACT

Before presenting to the Mayo Clinic, a 24-year-old white woman had received 35 transfusions of blood products over a 72-hour period in February 1981. Two and one half years later, the diagnosis of polymicrobial cholangitis (Cryptosporidium, Candida albicans, and Klebsiella pneumoniae) was established. Further evaluation demonstrated profound helper T lymphocyte suppression, disseminated Mycobacterium avium-intracellular infection with mycobacteremia, and Kaposi's sarcoma of lymphoid tissue, confirming a diagnosis of acquired immune deficiency syndrome (AIDS). This case represents an unusual infectious complication of AIDS. Additionally, this is believed to be the first report of Kaposi's sarcoma occurring in a patient with AIDS associated with blood product transfusion.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Cholangitis/complications , Acquired Immunodeficiency Syndrome/etiology , Adolescent , Candida albicans , Cholangitis/microbiology , Cryptosporidium , Female , Humans , Klebsiella pneumoniae , Sarcoma, Kaposi/complications , Transfusion Reaction
15.
Transplantation ; 43(1): 105-8, 1987 Jan.
Article in English | MEDLINE | ID: mdl-3541312

ABSTRACT

Monoclonal antibodies were used to identify T-helper cells (TH) and T-suppressor/cytotoxic cells (TS/C) in biopsy specimens obtained 7, 21, 90, 180, and 365 days postoperatively, and during episodes of graft dysfunction, from 34 consecutive liver transplant patients treated with cyclosporine and steroids. Rejection was diagnosed by the presence of appropriate laboratory and light microscopic findings and at least 8 weeks of follow-up to exclude other causes of graft dysfunction. Four immunohistologic patterns were seen--no labeled cells (No), only lobular TS/C, only portal TH, and a portal mixture of TH and TS/C (mix). Of 36 specimens with the No or only lobular TS/C pattern, 29 were not associated with rejection. Of the 39 specimens with the portal TH or portal Mix pattern, 33 were associated with a rejection episode. In addition, in nine specimens from patients with no biochemical or routine histologic evidence of rejection, the presence of portal TH or a portal mix indicated immunologic rejection 5 days to 5 weeks before biochemical and routine histologic evidence of it was manifested. Immunohistologic labeling appears to be an early indicator of liver allograft rejection.


Subject(s)
Liver Diseases/diagnosis , Liver Transplantation , T-Lymphocytes/immunology , Antibodies, Monoclonal , Biopsy , Graft Rejection , Humans , Immunity, Cellular , Liver Diseases/immunology , T-Lymphocytes/classification
16.
J Histochem Cytochem ; 38(4): 515-24, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2319122

ABSTRACT

Although recent data from our laboratory have established the occurrence of receptor-mediated endocytosis in intrahepatic bile duct epithelial cells (IBDEC) isolated from normal rat liver, no studies have assessed the role of isolated IBDEC in fluid-phase endocytosis. Therefore, to determine if IBDEC participate in fluid-phase endocytosis, we incubated morphologically polar doublets of IBDEC isolated from normal rat liver with horseradish peroxidase (HRP, 5 mg/ml), a protein internalized by fluid-phase endocytosis, and determined its intracellular distribution by electron microscopic cytochemistry. Pulse-chase studies using quantitative morphometry were also performed to assess the fate of HRP after internalization. After incubation at 37 degrees C, IBDEC internalized HRP exclusively at the apical (i.e., luminal) domain of their plasma membrane; internalization was completely blocked at 4 degrees C. After internalization, HRP was seen in acid phosphatase-negative vesicles and in acid phosphatase-positive multivesicular bodies (i.e., secondary lysosomes). Small acid phosphatase-negative vesicles containing HRP moved progressively from the apical to the basal domain of IBDEC. Pulse-chase studies showed that HRP was then discharged by exocytosis at the basolateral cell surface. These results demonstrate that IBDEC prepared from normal rat liver participate in fluid-phase endocytosis. After internalization, HRP either is routed to secondary lysosomes or undergoes exocytosis after transcytosis from the luminal to the basolateral cell surface. Our results suggest that IBDEC modify the composition of bile by internalizing both biliary proteins and fluid via endocytic mechanisms.


Subject(s)
Bile Ducts, Intrahepatic/cytology , Endocytosis/physiology , Liver/cytology , Animals , Bile Ducts, Intrahepatic/physiology , Bile Ducts, Intrahepatic/ultrastructure , Cell Separation , Chick Embryo , Cytoplasm/metabolism , Cytoplasm/ultrastructure , Epithelial Cells , Epithelium/physiology , Epithelium/ultrastructure , Horseradish Peroxidase/metabolism , Intracellular Membranes/metabolism , Intracellular Membranes/physiology , Intracellular Membranes/ultrastructure , Liver/physiology , Liver/ultrastructure , Lysosomes/metabolism , Lysosomes/ultrastructure , Male , Microscopy, Electron/methods , Rats , Rats, Inbred Strains
17.
Biochem Pharmacol ; 40(6): 1419-21, 1990 Sep 15.
Article in English | MEDLINE | ID: mdl-2403396

ABSTRACT

In vivo administration of chloroquine to rats caused an increase in the pH of hepatocyte lysosomes within 1 hr after administration with a return to baseline pH values by 3 hr; continued administration of chloroquine for up to 12 days was unaccompanied by any further changes in hepatocyte lysosomal pH. We interpret these data as evidence against a major role for an increase in the pH of hepatocyte lysosomes in CAC-induced phospholipidosis.


Subject(s)
Chloroquine/pharmacology , Liver/drug effects , Lysosomes/drug effects , Animals , Hydrogen-Ion Concentration , Injections, Intraperitoneal , Male , Rats , Rats, Inbred Strains
18.
Mayo Clin Proc ; 57(1): 44-50, 1982 Jan.
Article in English | MEDLINE | ID: mdl-7033682

ABSTRACT

The effect of administration of primary and secondary bile acids on absorption of cholesterol was investigated in 15 volunteers. Eight Caucasians with radiolucent gallstones were studied before and after administration of chenodeoxycholic acid (all eight) and cholic acid (eight before, six after treatment) for 3 months, and seven healthy subjects were studied before and five were studied after administration of deoxycholic acid for 6 weeks. The hourly absorption of [3H]cholesterol was measured for 24 hours in a 20-cm duodenal segment by use of an intestinal perfusion technique. Fasting serum cholesterol and triglyceride levels were also measured before and after administration of bile acid. In patients with gallstones, absorption of cholesterol in the duodenum, expressed as the mean (+/- SEM) percentage of [3H]cholesterol absorbed hourly for 24 hours, was not significantly different after administration of chenodeoxycholic (22.5 +/- 4.4%) or cholic (25.6 +/- 5.9%) acid when compared with the pretreatment value (21.1 +/- 4.3%). Moreover, administration of chenodeoxycholic and cholic acid did not affect serum lipid levels. In contrast, administration of deoxycholic acid to healthy volunteers suppressed [3H]cholesterol absorption (13.2 +/- 3.2%) compared with that of the pretreatment period (26.5 +/- 3.8%) and decreased serum cholesterol levels by 15%. Our results suggest that chenodeoxycholic acid decreases the concentration of cholesterol in bile and dissolves gallstones by a mechanism other than inhibition of absorption of cholesterol. The data also indicate that the hypocholesterolemic effect of deoxycholic acid is due to the inhibition of intestinal absorption of cholesterol.


Subject(s)
Chenodeoxycholic Acid/pharmacology , Cholesterol/metabolism , Cholic Acids/pharmacology , Deoxycholic Acid/pharmacology , Intestinal Absorption/drug effects , Adult , Bile/drug effects , Bile/metabolism , Cholelithiasis/metabolism , Cholesterol/blood , Clinical Trials as Topic , Female , Humans , Male , Perfusion , Triglycerides/blood
19.
Mayo Clin Proc ; 50(12): 706-8, 1975 Dec.
Article in English | MEDLINE | ID: mdl-1195781

ABSTRACT

A 46-year-old man with chronic diarrhea underwent exhaustive investigations, including laparotomy, but a definitive diagnosis could not be made. It was not until a colonoscopic biopsy demonstrated the pigment of melanosis coli that the surreptitious use of laxatives was considered seriously. This diagnosis was confirmed by simple chemical tests that demonstrated phenolphthalein in the feces and urine.


Subject(s)
Cathartics/adverse effects , Diarrhea/chemically induced , Substance-Related Disorders , Feces/analysis , Giardiasis/complications , Humans , Male , Middle Aged , Phenolphthaleins/urine , Potassium/blood
20.
Mayo Clin Proc ; 55(7): 450-4, 1980 Jul.
Article in English | MEDLINE | ID: mdl-7382555

ABSTRACT

A 21-year-old woman with recurrent epidsodes of pruritus and jaundice since childhood was diagnosed as having benign recurrent cholestasis, a rare and poorly understood disease. Plasmaperfusion was successfully employed for therapy of the severe pruritus, and various studies of copper metabolism were performed in an attempt to clarify the pathophysiology of this obscure syndrome.


Subject(s)
Cholestasis/metabolism , Copper/metabolism , Hemoperfusion , Pruritus/therapy , Adult , Cholestasis/blood , Cholestasis/physiopathology , Copper/blood , Female , Hemolysis , Humans , Liver/metabolism , Plasma , Recurrence , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL